Omega-3 fatty acids (EPA and DHA) lower inflammation, support heart rhythm, and build the structural scaffolding of brain cells. We treat omega-3 as a biomarker-driven intervention instead of a guess: we measure your Omega-3 Index, a blood test that reflects EPA and DHA saturation inside your red blood cell membranes, and dose to a target of 12 to 15% - higher than the conventional >=8% floor, because that range matches the tissue saturation seen in populations with high marine intake (such as Japanese coastal communities) and the lowest cardiovascular event rates. Moving from ~4% to >=8% takes 1,300 to 1,600 mg/day of re-esterified triglyceride (rTG) EPA+DHA (or 1,800 to 2,000 mg/day of ethyl esters), and reaching 12 to 15% typically takes 2,000 to 3,000 mg/day alongside oily fish. The main cautions are mild blood thinning and, above 1.5 to 4 grams/day in high-risk heart patients, a dose-dependent increase in atrial fibrillation risk.
Almost every week in Fishtown, a new patient sets a giant warehouse bottle of "1,000 mg" lemon-flavored fish oil on my desk and wonders why their red-cell Omega-3 Index came back at 4.3%. When we flip the bottle over, each softgel carries only 300 mg of ethyl-ester EPA + DHA, they have been taking it on an empty stomach with black coffee (wasting four-fifths of the dose), and the lemon flavoring is masking oxidized oil. Treating omega-3 like a biomarker - checking whether your lab ran the red-cell Omega-3 Index (target 12 to 15%) or Quest's whole-blood OmegaCheck (target 7 to 10%), and dosing unflavored triglyceride (rTG) oil with dinner - turns a blind habit into measurable heart and brain protection.
What omega-3 is and what it does
Omega-3 fatty acids are healthy fats your body cannot build for itself, which means every bit of it arrives through what you eat or what you take. For adults, the 2 that matter are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), and you get them mainly from oily fish like salmon, sardines, and anchovies, or from algae oil. Once they are in you, they get built into your cell membranes, bring your triglycerides down, and lower inflammatory cytokines. They also hold up the structure of brain and heart tissue, and the signaling that tells inflammation when it is time to stop.
Make sure you are reading the right test
Before you compare your result to any target on this page, check which test you were given, because 2 different ones are in common use and they do not share a scale.
The Omega-3 Index measures EPA and DHA inside red blood cell membranes. That is the test every number on this page refers to, including the 12 to 15% target.
OmegaCheck, which is what Quest runs on many panels, measures EPA plus DPA plus DHA in whole blood. It includes a third fatty acid the Omega-3 Index leaves out, and it samples whole blood instead of isolated red cells, so it reports on a lower scale where roughly 5.5% or above is lab optimal (and Fishtown Medicine targets 7 to 10%).
The 2 track the same biology closely, with a correlation around 0.91. They remain separate numbers on separate scales. If you hold a Quest result reading 3.9% and measure it against a 12 to 15% target, you will conclude you are far worse off than you are, and you will keep raising your dose chasing a number that assay cannot produce. A later result of 7.5% on that scale is a strong outcome.
So: if you want to track against the target here, ask for the Omega-3 Index specifically. If your report says OmegaCheck, read it against our 7 to 10% target (or the 5.5% lab floor), and tell us which test you had so the plan matches the scale.
The blood test I care about most in this conversation is the Omega-3 Index. It measures how saturated your red blood cell membranes are with EPA and DHA. That tells us what your tissue levels have been across the past 120 days, instead of what you ate for dinner yesterday. Here is how I read your result:
- High-risk (under 4%): this is the range that gets my attention. Down here you carry a higher statistical risk of sudden cardiac events (Siscovick JAMA 1995 OR 0.30; Harris 2017), and any chronic inflammation you have is running with very little pushing back against it.
- Intermediate (4 to 8%): most new patients walk in somewhere in this band (US mean ~4.5%). It is "standard" for how Americans eat, which is a low bar to clear, and it leaves you a lot of room to work with.
- Guideline-acknowledged "low risk" floor (8 to 12%): the conventional Harris/von Schacky target. Across 17 prospective cohorts (FORCE Consortium, Harris et al., Nature Communications 2021, n = 42,466), top-quintile blood EPA + DHA carried 16% lower all-cause mortality (HR 0.84) and 20% lower cardiovascular mortality (HR 0.80) (31% to 34% lower death in WHIMS and Framingham Offspring), plus +159 mm3 larger hippocampal volume on brain MRI (WHIMS-MRI, Pottala et al., Neurology 2014).
- FTM target (12 to 15%): the saturation seen in populations with high marine intake, like Japanese coastal communities, whose cardiovascular and dementia event rates have historically been the lowest anywhere. It is where I aim, using a Rx-grade or third-party-tested formulation, and I bring up the AF caveat out loud every time instead of tucking it into a footnote.
- Above 15%: historically this was Inuit territory, where extreme marine intake was simply the diet. Climbing toward 18% buys you nothing measurable, the benefit curve has already flattened by then, so I do not push you up here without a specific clinical reason.
EPA and DHA are not interchangeable, and the ratio you pick should follow what you are trying to fix. EPA is the main driver for mood support and for bringing systemic inflammation down. DHA is the structural scaffolding of your brain and your retina. That makes it the priority when we are protecting cognition, supporting a pregnancy, or helping you come back from a concussion or a traumatic brain injury (TBI). Eye health comes with a wrinkle worth understanding: eating fish is linked with lower macular degeneration risk, while omega-3 supplements showed no benefit in the AREDS2 trial. For mood that looks inflammation-driven, I look for a 4:1 EPA to DHA ratio, or at least 60% EPA. For neuroprotection, I want you at 600 to 1,000 mg of DHA a day or better.
Who this is for (and who it isn't)
Omega-3 fits a wide range of adults. These are the situations where I bring it up early:
- Most Philly adults who don't eat oily fish 3 or more times per week. Cheesesteaks, hoagies, pretzels, and pizza hand you all the omega-6 fat you could ask for and almost no omega-3. That is most weeks for most of us here, and when it is, a supplement is usually the simplest correction.
- Heart and metabolic health patients. At 2,000 to 4,000 mg a day, omega-3 reliably brings your fasting triglycerides down by 20 to 30%. That is often further than you can get by changing how you eat alone, and it also pulls down remnant cholesterol, the atherogenic fraction a standard lipid panel never prints.
- Brain and mood support. In randomized trials, higher-EPA formulations at 1,000 to 2,000 mg of EPA a day have shown modest benefit for depression, added on top of standard treatment.
- Joint and autoimmune conditions. At 2,000 to 4,000 mg a day, higher omega-3 intake is linked with less joint pain in rheumatoid arthritis and with modest improvement in psoriasis. When joints are the whole reason you are here, boswellia blocks a different inflammatory enzyme and stacks with this without repeating it.
- APOE4 carriers. If you carry APOE4, the variant that raises your Alzheimer's risk, we go higher, 2,000 to 3,000 mg. I also push salmon roe or oily fish, because those give you omega-3 in the phospholipid form (LPC-DHA), which crosses the blood-brain barrier via the Mfsd2a transporter more efficiently (PreventE4 trial Yassine Lancet Healthy Longev 2026).
There are also a few situations where we talk it through first, or start you somewhere else:
- You take a blood thinner (Eliquis, Xarelto, warfarin, daily aspirin), or you have a bleeding disorder. Omega-3 thins the blood modestly on its own, so the dose and the monitoring get coordinated instead of stacked.
- You have a history of atrial fibrillation. Across 35 randomized trials (Gencer Circulation 2021, n = 81,210; Abuknesha 2026, n = 114,592), doses above 1,000 to 1,500 mg/day in high-risk cardiac patients increase AFib risk by 43% to 49% (OR 1.43 / HR 1.49, +11% per additional gram/day), and your cardiologist belongs in that decision with us.
- You have surgery scheduled in the next 7 to 14 days. Most surgeons want fish oil stopped before an elective procedure to lower bleeding risk, so we plan around the date.
How we evaluate it: do you need it, is it safe, does the dose work, then cost
Every supplement we recommend runs the same 4 gates, in order, and most things never make it past the first one (the whole process is in how we choose supplements).
- Do you need it? The Omega-3 Index decides this. Most people walk in somewhere between 4 and 8%, which leaves a lot of room to work with, and an index already in the 12 to 15% range means you can keep your money. An index of 3 falls in the high-cardiovascular-risk band and is one of the more actionable findings on a panel.
- Is it safe (GOED / IFOS Oxidation & TOTOX < 26)? I want third-party testing on the bottle, either IFOS 5-star (International Fish Oil Standards) certification or USP verification. International GOED freshness limits require a Peroxide Value (PV) < 5 meq O2/kg, p-Anisidine Value (p-AV) < 20, and TOTOX (2xPV + p-AV) < 26. In a multi-year analysis of 72 US supplements (Hands et al., 2024), 68% of flavored fish oils vs. 13% of unflavored oils exceeded TOTOX limits (because added flavorings both mask rancidity and interfere with the p-AV assay), and in human crossover data (Rundblad et al., Br J Nutr 2017), only unoxidized high-quality oil improved IDL and LDL particle subclasses. Pick unflavored oils, and if a bottle smells strongly fishy, throw it out.
- Does the dose work (rTG vs. EE bioavailability)? Your one-a-day multivitamin probably carries 300 mg of fish oil, which is far too small a dose to move a biomarker. Read the combined EPA plus DHA per serving instead of the total fish oil figure printed on the front. In a 14-trial dose-response analysis (Walker et al., AJCN 2019, n = 1,422), moving from ~4% to >= 8% takes 1,300 to 1,600 mg/day in re-esterified triglyceride (rTG) form (~124% relative bioavailability, raising the index ~1 percentage point more per gram than ethyl esters), compared with 1,800 to 2,000 mg/day in ethyl ester (EE) form (~73% bioavailability, where absorption is 3x higher with a high-fat meal than a low-fat meal, Lawson & Hughes 1988).
- How we source it: Once we narrow the field to pure, unflavored, third-party-tested rTG or algae options, we pick the most cost-effective bottle per gram of EPA + DHA.
- What we make on it: nothing. Our only charge is the flat membership fee, and nothing is ever added on top of it. We take nothing on supplements, labs, imaging, or medication, which means every discount we can negotiate reaches you at cost. There is no conflict of interest here to work around, so the 4 gates above are the only things deciding what you hear from us.
How to dose it, and when
Read the label for combined EPA plus DHA, because a softgel sold as "1,000 mg fish oil" may carry only 300 mg of omega-3s.
- Foundational. I usually start you at 2,000 mg of total EPA and DHA daily, which is typically 2 large softgels of rTG oil, and we build from there.
- Therapeutic. If your triglycerides are high, or we are working on an autoimmune condition, we may titrate up to 4,000 mg daily with close supervision.
- APOE4 protocol. 3,000 to 4,000 mg daily, weighted toward phospholipid-form sources like salmon roe and oily fish.
- Take it with fat. Omega-3s are fat-soluble, and the difference is large enough to change your result. Alongside a meal containing fat you absorb the large majority of what you swallow; on an empty stomach with black coffee you may keep only a fifth of it. The simplest version is to take it with the first meal of the day that carries some fat, and if you take vitamin D as well, the same meal covers both. Avocado, olive oil, eggs, and salmon all do the job. On a day when the ideal meal never shows up, take it anyway, because a consistent habit at lower absorption still beats a perfect one you keep skipping.
- Consistency beats timing. These fats saturate your cell membranes over weeks, so a missed dose is no crisis. What fills the reservoir is taking it steadily.
Triglycerides and joint stiffness can change within 4 to 8 weeks. Moving your Omega-3 Index from a low value up into the 12 to 15% target usually takes 3 to 4 months of daily dosing, because red blood cells turn over slowly. We retest at month 3 to confirm you got there.
Cerebrovascular and stroke evidence
Stroke is a more nuanced story than sudden cardiac death, and it only makes sense once you separate observational biomarker data from RCT supplementation data.
- Observational, biomarker-based: A pooled analysis of 29 prospective cohorts covered 183,291 participants and 10,561 strokes. Compared with the lowest quintile of EPA, the highest quintile was associated with a 17% lower total stroke risk (HR 0.83) and an 18% lower ischemic stroke risk (HR 0.82). DHA moved the same direction, a little more weakly.
- RCT, supplementation-based: A Cochrane review of 31 trials found that omega-3 supplementation made little or no difference to stroke risk (RR 1.02).
- The exception: EPA monotherapy. In REDUCE-IT, prescription icosapent ethyl at 4 g/day cut non-fatal stroke by 29% (RR 0.71) in patients who already had cardiovascular disease or diabetes and were already taking a statin. The EPA+DHA combination products have not reproduced it.
Dose and target explain most of the gap. The trials that showed nothing used mixed EPA/DHA capsules at modest doses without measuring or targeting the Omega-3 Index. The trials and biomarker cohorts that showed a signal ran higher EPA fractions and / or sustained high tissue saturation. That is why we measure your O3I instead of guessing at it.
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can follow.
Both guideline bodies read that negative-trial evidence the way you would expect. The 2024 AHA/ASA Primary Prevention of Stroke Guideline assigned a Class 3 (no benefit) recommendation for omega-3 supplementation for stroke risk reduction. The 2026 ACC/AHA Dyslipidemia Guideline carries a separate Class 2b recommendation for icosapent ethyl (4 g/day). It applies to adults 50 and older with established ASCVD, or diabetes plus another risk factor, along with persistent TG 150-499 mg/dL and LDL under 100 on a maximally tolerated statin. We respect both positions, and our practice pattern still runs ahead of the formal criteria, because we are treating to an Omega-3 Index biomarker target instead of waiting for the trial-defined entry conditions.
How we use omega-3 in clinic (and why we move earlier than the Class 2b criteria)
Our clinical position is that omega-3 does reduce MACE and stroke risk - when product quality, dose, and biomarker targeting are right. Read the null trials closely. What they indict is under-dosed, poorly-characterized OTC fish oil given without measuring tissue levels, not omega-3 itself. Most of them used around 1 g/day of mixed EPA+DHA, the same exposure profile the biomarker cohorts call "low risk." That is the protocol those trials studied. It is not the protocol we use.
The supporting case for our position:
- REDUCE-IT (icosapent ethyl 4 g/day, pharmaceutical-grade EPA) showed a 25% MACE reduction, an NNT of 21 over 4.9 years, and a 28% reduction in stroke as a secondary outcome. Quality and dose were doing that work.
- The biomarker data (Omega-3 Index, EPA and DHA tissue levels) ties higher levels to lower MACE, stroke, and all-cause mortality across hundreds of thousands of participants, and it does so consistently. In the Framingham Offspring analysis, the top O3I quintile came in with 39% lower incident CVD.
- The 2024 stroke-prevention Class 3 position and the 2026 Class 2b dyslipidemia position both rest heavily on trials that used mixed EPA+DHA at 1 g/day or less without biomarker targeting. That is essentially the same "low risk" exposure profile again.
What we prescribe:
- Lovaza (omega-3 acid ethyl esters, EPA+DHA Rx) when insurance covers it. Its FDA approval is for triglycerides over 500 mg/dL. We use it for ASCVD and cerebrovascular risk reduction in selected patients, because the formulation is pharmaceutical-grade and we know what is in it.
- Icosapent ethyl (Vascepa) at 4 g/day if you meet the REDUCE-IT criteria: established ASCVD or diabetes plus a risk factor, already on a statin, LDL 41-100, TG 150-499, with insurance willing to cover it. Of everything on this page, that is the path with the clearest single trial standing behind it.
- Specific pure, third-party-tested EPA+DHA formulations at 2-3 g/day, dosed to bring your Omega-3 Index up into the 12-15% range. Generic OTC fish oil stays off the list. The dose, oxidation state, and EPA:DHA ratio vary from bottle to bottle, and that exposure is what produced the null outcomes data.
- We start earlier than the formal Class 2b criteria when you have high ApoB, residual ASCVD risk, a family history of early MI or stroke, or a measured low O3I, whatever your triglycerides happen to be doing. We are treating to a biomarker target instead of waiting for trial-defined entry criteria.
- We surface the AF risk directly. Both EPA-only and EPA+DHA raise AF risk in a dose-dependent way, particularly above about 1 g/day. In REDUCE-IT, hospitalization for AF ran 3.1% on IPE against 2.1% on placebo, an NNH of roughly 91, and among patients with prior AF the gap was much wider, 12.5% against 6.3%. So if you have a history of palpitations, prior AF, or a pacemaker, you and I have that risk-benefit conversation out loud before anything gets added.
For the broader stroke and MACE primary-prevention picture, see the Stroke Prevention guide.
Flaws, side effects, and interactions
No supplement is perfect, and naming the downsides is part of the job.
- Fish burps and reflux. Usually this means the oil is oxidized (rancid), it is in ethyl ester form, or you took it on an empty stomach. Switching to a rTG brand, freezing the capsules, and taking them with your largest meal settles it most of the time, and enteric-coated softgels, which dissolve in the small intestine, are another option. If the bottle smells strongly fishy, throw it out.
- Mild blood thinning. Omega-3s have a mild anti-platelet effect. Highly saturated cell membranes are good for blood flow generally, but your clotting time does lengthen a little, so we plan a washout of 7 to 14 days before scheduled surgery.
- Blood thinners. Taking omega-3 alongside prescription blood thinners (Eliquis, Xarelto, warfarin, daily aspirin) can raise your bleeding risk. We often keep the dose modest, around 1 gram per day, and watch for unusual bruising.
- Atrial fibrillation. High-dose omega-3, around 4 grams per day, has been linked with a small bump in atrial fibrillation risk. REDUCE-IT and STRENGTH both show the rhythm risk rising slightly while major cardiac events generally fall. For metabolically healthy patients the cognitive and longevity benefits usually outweigh that, and if AFib is part of your history we coordinate with your cardiologist. If you feel a thumping or a skip in your chest, tell me and we adjust right away.
- LDL cholesterol. Some patients see a small rise in LDL when they start high-dose omega-3, particularly on DHA-heavy products. I confirm with an ApoB test, which counts the harmful particles. If ApoB is rising along with LDL, we adjust the formulation or the dose.
- Statins. Omega-3 does not block statins. The combination has its strongest data in people with stubbornly high triglycerides or known plaque on imaging.
What we recommend, and what we don't
- We look for: the re-esterified triglyceride (rTG) form, IFOS or USP certified for purity and freshness, with a verified combined EPA plus DHA dose printed on the label. If you eat plant-based, or fish does not agree with you, algae oil gives you bio-identical EPA and DHA from the same algae the fish eat to build their own omega-3.
- Worth considering: krill oil, which delivers omega-3 in the phospholipid form and absorbs efficiently, if cost is less of a concern. Prescription Vascepa (icosapent ethyl, 4 grams per day) is purified EPA only, and it carries strong randomized trial data for reducing major cardiac events in high-risk patients on a statin who have high triglycerides. We choose between them based on your risk profile, your insurance, and your lab values.
- We avoid: one-a-day multivitamin fish oil at 300 mg, which is too small to move a biomarker, and ethyl ester bulk oils with no third-party testing. We also avoid ALA from flax or walnuts as a substitute, since you convert under 5% of it to EPA and DHA and usually fall short. And we do not go above 4,000 mg per day without a clear rationale and a way to monitor.
Guidance from the Clinic
"I often see patients taking fish oil for years, yet their Omega-3 Index is still stuck at 4%. Usually, it is a dosing or absorption issue. It is not enough to swallow the capsule. We need to verify that the EPA and DHA are getting into your cell membranes. Read for combined EPA plus DHA, pick the rTG form, take it with a full meal, and recheck your index at 3 months. That is most of the game."
Dr. Ash
Actionable Steps
Get omega-3s that move your biomarkers.
- Test before you supplement. Order a baseline Omega-3 Index to know your starting point and set a clear target.
- Read for EPA plus DHA. Ignore the total oil number on the front; add up the active fats on the supplement facts panel.
- Pick the rTG form, third-party tested. Re-esterified triglyceride for absorption, IFOS or USP for purity and freshness.
- Take it with your largest meal. Fat in the meal drives absorption; an empty stomach wastes most of the dose.
- Recheck at 3 to 4 months. Track the Omega-3 Index toward 12 to 15% and adjust dose accordingly.
Key Takeaways
- Omega-3 (EPA and DHA) is a biomarker-driven intervention: Fishtown Medicine measures the Omega-3 Index and doses to a target of 12 to 15%, above the conventional 8 to 12% guideline floor, instead of guessing from a fixed pill count.
- Moving from ~4% to >= 8% takes 1,300 to 1,600 mg/day of rTG EPA + DHA (Walker 2019), and reaching 12 to 15% typically takes 2,000 to 3,000 mg/day alongside oily fish; therapeutic targets (high triglycerides, autoimmune) may use up to 4,000 mg/day.
- Choose an unflavored re-esterified triglyceride (rTG) form with IFOS 5-star or USP certification (TOTOX < 26), and take it with a fat-containing meal.
- The main cautions are mild blood thinning (7 to 14 day washout before surgery) and a dose-dependent atrial fibrillation risk above 1.5 to 4 g/day in high-risk cardiac patients (Gencer 2021; Abuknesha 2026).
- Recheck the Omega-3 Index at 3 to 4 months (12 to 16 weeks) and adjust dose to reach the 12 to 15% target (or 7 to 10% on Quest OmegaCheck).
If you'd like us to source it for you:
A note on cost: any discount we negotiate on professional-grade supplements passes straight through to you, with no markup. Here is how we choose and source supplements.
Scientific References
- Harris WS, Del Gobbo L, Tintle NL. (2017). The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. Atherosclerosis, 262, 51-54. PubMed
- Harris WS, Tintle NL, Imamura F, et al. (2021). Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies (FORCE). Nature Communications, 12(1), 2329. DOI
- Walker RE, Jackson KH, Tintle NL, et al. (2019). Predicting the effects of supplemental EPA and DHA on the Omega-3 Index. American Journal of Clinical Nutrition, 110(4), 1034-1040. PubMed
- Bhatt DL, Steg PG, Miller M, et al. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 380, 11-22. DOI
- Nicholls SJ, Lincoff AM, Garcia M, et al. (2020). Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH). JAMA, 324(22), 2268-2280. DOI
- Gencer B, Djousse L, Al-Ramady OT, et al. (2021). Effect of long-term marine Omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes. Circulation, 144(25), 1981-1990. PMC
- Abuknesha NR, O'Keefe JH, Qian F, et al. (2026). Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials Including 114,592 Individuals. Circulation: Arrhythmia and Electrophysiology. PubMed
- Hands JM, Anderson ML, Cooperman T, Frame LA. (2024). A Multi-Year Rancidity Analysis of 72 Marine and Microalgal Oil Omega-3 Supplements. Journal of Dietary Supplements, 21(2), 195-209. PubMed
- Rundblad A, Holven KB, Ottestad I, Myhrstad MC, Ulven SM. (2017). High-Quality Fish Oil Has a More Favourable Effect Than Oxidised Fish Oil on Intermediate-Density Lipoprotein and LDL Subclasses. British Journal of Nutrition, 117(9), 1291-1298. PubMed
- Yokoyama M, Origasa H, Matsuzaki M, et al. (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS). Lancet, 369(9567), 1090-1098. PubMed
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





